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ABSTRACT
MARKOV DECISION PROCESS APPROACH TO STRATEGIZE NATIONAL BREAST
CANCER SCREENING POLICY IN DATA-LIMITED SETTINGS
SEPTEMBER 2019
VIJETA DESHPANDE,
B.E. UNIVERSITY OF PUNE,
M.S. UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Chaitra Gopalappa

Rising rates of cancer incidence and mortalities in low and middle-income countries
(LMICs) are burdening the already strained health care systems in LMICs. As cancer rates
are expected to continue to rise, to better cope with this rapidly changing landscape,
countries are working on incorporating cancer control programs, including early detection,
as part of their national strategic planning. In the absence of control programs, cancers
mostly get diagnosed in the advanced stages when they become symptomatic. While
treatment in early stages of cancer are mostly effective, treatment in advanced stages is
complex, expensive and mostly ineffective. Therefore, early diagnosis is a promising
strategy to reduce premature mortalities and for optimal use of resources. But the absence
of mathematical models specific to the data settings in LMIC’s impedes the construction
of economic analysis necessary for decision-makers in the development of cancer control
programs. This thesis presents a new methodology for parameterizing the natural history
model of breast cancer based on data availabilities in low and middle income countries,
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and formulation of a control optimization problem to find the optimal screening schedule
for mammography screening, solved using dynamic programming. As harms and benefits
are known to increase with the increase in the number of lifetime screens, the trade-off was
modeled by formulating the immediate reward as a function of false positives and lifeyears saved. The method presented in thesis will provide optimal screening schedules for
multiple scenarios of Willingness to Pay (numeric value assigned for each life-year lived),
including the resulting total number of lifetime screens per person, which can help
decision-makers evaluate current resource availabilities or plan future resource needs for
implementation.
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CHAPTER 1
INTRODUCTION AND BACKGROUND
1.1 Cancer trends and burden in low and middle-income countries
Twenty years ago, communicable diseases such as HIV, malaria and tuberculosis were the
primary concerns for low and middle-income countries (LMICs) and non-communicable
diseases (NCDs) such as chronic heart and respiratory diseases, diabetes, and cancers, had
negligible if any spotlight in overall disease burden in LMICs (1). But from 1990 to 2010,
cancer fatality in LMICs increased to 7.98 million in 2010, compared to the previous
decade, is was a 38% increase in cancer-related deaths in LMIC, which constituted a 15.1%
portion of all global deaths in 2010 (1). Also, newly reported cancer cases in LMICs
increased from 15% in 1970 to 56% in 2008, and such incremental trends are expected to
continue to an estimated 70% by 2030 (1) (2). These increases are generating tremendous
burdens on health care systems. Also, more than 60% of cancer related deaths occurred in
LMIC and only 5% of global health resources for cancer are spent there (1) (2) (3). Hence,
it is essential than ever to develop cost effective cancer control strategies specific to LMIC.
The general recommended approach to cancer control, based on cost-effectiveness
estimates, is to first prevent the cancers which can be prevented, second, to treat the cancers
which can be cured and third, to palliate the cancer when the first two approaches fail (1).
Prevention programs have high potential to reduce the incidence of cancer by 33-50% (1).
For several cancers, life can be considerably extended with low-cost drug treatment, e.g.
pancreatic and lung cancer. When treatment is not always a feasible option, palliation
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through reduction in pain and suffering is deliverable in low cost (3). But many cancers
out of all those which are responsible for the most burden on LMIC health system are
amenable to treatment e.g. colorectal cancer, cervical cancer and breast cancer (2).
Among all cancers, the highest disease burden in women is from breast cancer (4). Global
breast cancer incidence in 2012 (43.3 per 100,000) was estimated to be 3 times that of the
next most common cancers in women, namely, colorectal cancer, lung cancer, and cervical
cancer with 14.3, 13.6, and 14.0 cases, respectively, per 100,000 persons (4). East and
Central Asia reported the highest proportion of global breast cancer burden, about 36.3%
and 41.5% of recorded incidence and deaths, respectively (4). Latin America and the
Caribbean experienced 9.1% cases and 8.3% deaths of the global count (4).
The population attributable factor (PAF), defined as the contribution of a risk factor to a
disease or a death, of breast cancer is 27% for high-income countries and 18% for low
middle-income countries (5). Solin et. al. (6), present results on selective screening
(according to risk factors such as previous breast biopsy and family history of breast
cancer) for breast cancer. In the simulation of screening of 17,543 women, more than 50%
of the cases would not have been detected if it was a selective screening. Madigan et.al. (7)
and De Waard et.al. (8) present evidence for the fact that only small proportion of the total
breast cancer cases are related to the known risk parameters for breast cancer. Evidence
collected from above mentioned studies argues that the sub-setting of women population
based on the known risk-factors of breast cancer will not successfully identify the target
group for mammography screening. On the other hand, cancer control largely depends on
early detection due to the morbid, expensive and often ineffective nature of treatment in
advanced stages of cancer (9). Hence, given that there are less known attributable risk
2

factors for breast cancer, the next best strategy for breast cancer control is conducting
mammography screening programs with age-based invitation (4).
1.2 Screening programs and practices in high-income countries and low and middleincome countries

Screening programs can either be organized or opportunistic. Organized screening
programs are those which does have clear invitation protocol to a well-defined target
population, systematic call and recall for screening, investigation of results, follow-up
treatments, quality tracking and program database (4). Dissemination of tracking and
investigating team is also a trait of organized screening programs. Opportunistic programs
do not target any subset of population but work with recommendations from regular health
check-ups, therefore dependent on primary health care providers. Organized programs are
generally evident in high income countries and opportunistic programs in low income
countries.
Most of the organized programs for breast cancer approximately target the population in
age group 40-74 years with biennial frequency of screening (4) (10). But this screening
schedule greatly depend on the demographics and the epidemics specific to the population.
Some high-income countries recommend populations in the younger age-group than 50
years of age for screening while others do not. While screening in age group 50-69 is
strongly recommended for high-income countries by WHO recommendations, invitation
to women in age-group 40-49 for mammography screening is conditional (11). For lowmiddle income countries, WHO recommends not to screen women in age group 40-49 and
screening in age group 50-69 is conditional upon the scale and scope of the healthcare
systems.
3

The next sub sections will briefly discuss the practices in different high and low-middle
income countries and will point towards the observed positive outcomes of screening
programs in high-income countries and the discrepancies between the WHO recommended
guidelines and the current practices in low-middle income countries.
1.2.1 Practices in high-income countries and outcomes

Countries such as United States, United Kingdom, Finland, Netherland, Canada have
achieved established (approximately 25 years old) organized breast cancer screening
programs. In 2007, 26 of the 27 members of states in European Union (former) had an
active breast cancer screening program, out of which 22 were organized. Seventy nine
percent of the eligible population in these 26 countries were covered under regular
screening (mammography) programs, most of the screened population was covered with
no or little cost for women undergoing screening. All of the countries in EU recommend
screening for women in age group 50 to 59 years, some countries additionally recommend
40 to 49 and/or up to 74 years of age. The frequency of screening is biennial for all the
countries but UK and Malta, while in Austria, yearly screenings are also evident (4). In the
case of Canada, all provinces have organized screening programs but Nunavut. British
Columbia started the program in 1988 while Northwest territories started their program in
2003. Opportunistic screenings are available in those facilities which are not included in
the organized screening program. All provinces and territories in Canada recommend
women in age-group 50-69 for biennial screening and similar to EU selective screening for
women under 50 years of age and over 70 is also available on basis of recommendations
from practitioners (4). In the USA, promotion of mammography screening started in late
1980s and early 1990s. Since 1991, biennial screening was recommended and covered in
4

Medicare insurance plan. Private insurances covered mammography screening costs fully.
The proportion of population not covered in Medicare and private insurance plans faced
financial barrier for screening, but most of the issues, not all, in these barriers were resolved
by the introduction of the Affordable Care Act(ACA) (4).
In these high-income countries, incidence of breast cancer sharply increased from 1980 to
2000 and mortality rates decreased consistently between 1990 to 2010 (12). Both the
outcomes are majorly related to increasing prevalence of mammography screening from
1980 to 2005 (12). An estimated 28% to 65% reduction in mortality rates is expected to
have occurred because of early detection and the rest proportion due to the systematic
treatment (13). (Variability in the estimates of different models is associated with the
difference in the modeling approach and assumptions.)
1.2.2 Practices in low and middle-income countries

Unlike in high-income countries, screening programs in low and middle-income countries
have not yet reached to the scale where it can be considered as an organized program. Some
countries in Asia, such as China and Indonesia, have local community-based screening
programs (4). In the case of India, screening programs are restricted to controlled study
purposes only, but educational/awareness programs are promoted (not specific to breast
cancer) widely (4). Except South Africa, none of the countries in the Sub-Saharan African
region have developed any screening guidelines for the population. Participation in
screening programs of breast cancer in South Africa is also very low, approximately 15%
of women reported having at least one mammogram in lifetime (4). In Central and West
Asia and North Africa, most of the countries are categorized as low and middle income, in
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these countries resource allocated to healthcare is limited and screening is rarely available
(4).
Latin American countries have increased awareness towards the changing epidemiology of
cancer and most of the countries where breast cancer is the leading cause of death, have
developed screening guidelines for population. Most of the countries recommend self and
clinical breast examination along with mammography for screening (4). Screening
recommendations in most Latin American countries is for age-group 50-70, along with self
or clinical examination for the younger age-groups. In few Latin-American countries,
screening recommendation for women in age-groups 40-49 years is conditioned on breast
cancer history while for few others, it is unconditioned(4) (14). But the opportunistic or
regional organized screening programs inspired from such recommendation in LatinAmerican countries have not produced the similar reduction in the mortality rates as
observed in high-income countries (9).
WHO Position Paper on Mammography Screening (11), recommends screening only for
those lower-middle income countries which does have strong health systems, i.e. health
systems having capacity to gradually develop and sustain an organized screening program.
Recommended guidelines suggest conditional screening for age-group 50-69 and
guidelines strongly recommends against screening the age-group 40-49 (11). However,
certain countries such as Peru, a lower middle-income country, has developed legislative
framework for early diagnosis, treatment and follow-up in 2008 which includes screening
for women aged 40 years and older (15). The current evidence-based recommendations
and practices of screening in low-middle income settings greatly vary. Majority of the
evidence provided for development of the guidelines are either synthesized from the data
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from randomized control trials conducted in high-income countries or extrapolation of the
modeling studies conducted for high-income countries (11).
Therefore, it is essential to inform the development of the screening programs with
evidence collected from studies which extensively and exclusively consider all aspects of
the low-middle income settings.
1.3 Global action plan for non-communicable diseases (NCDs)

In 2008, 63% of the global deaths occurred due to NCDs out of which 38% were premature
(before the age 70) and 90% of the premature deaths occurred in low and middle-income
countries. Considering the changing trends and shifting burden of NCDs towards low and
middle-income settings, the 66th World Health Assembly endorsed the global action plan
proposed by World Health Organization for prevention and control of NCDs. The goal of
the Global Action Plan is to reduce the burden in the form of morbidity, mortality and
disability due to non-communicable diseases, through collaboration at regional, national
and global level, so that populations will reach the highest attainable levels of health and
productivity, ensuring the socioeconomic growth. The global action plan offers a paradigm
shift by providing a road map and a menu of policy options for UN Member States, WHO,
other UN organizations and intergovernmental organizations, NGOs and the private sector
which, when implemented collectively between 2013 and 2020, will attain 9 voluntary
global targets, including a 25% relative reduction in premature mortality from NCDs by
2025 (16).
1.4 Intrinsic challenges in mammography screening
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As stated before, screening programs have resulted in reduction of mortality rates in highincome countries. When a screening program is organized, even though asymptomatic
patients benefit from it, a large proportion of the screened population do not experience
any benefit from screening, which encourages the questions of resource (screening
resource with auxiliary support staff) management, utilization improvement and target
group selection. In the case of breast cancer, as it is difficult to determine target group with
currently known risk factors (5), resource management is a challenging task.
When a large proportion of screened population is not benefitting from the screening,
ideally, they also should not experience any harms from it. In fact, screened population
might be exposed to addition health risks or even death as a result of screening (17) . Some
health risks are embarked upon screened person with the false positive result of the test,
which are followed up with more clinical procedures and also causes short term
psychological distress (4). Other health risks are due to diagnosis of cancer which never
would have caused death or any degradation of quality of life (17) . There is sufficient
evidence that women in age group 50-69 are diagnosed with cancer which never would
have been diagnosed or caused any harms if the women had not been screened (4). In other
words, when woman undergoes screening she reduces the risk of death due to cancer but
also accepts the risk of over diagnosis and overtreatment, hence, assessment of risks and
benefits is of significance. There is sufficient evidence that mammography screening is
cost effective in the 50-69 age group in the population with high incidence but, importantly,
there is limited evidence available for cost-effectiveness of the mammography screening
in low and middle-income settings, as the incidence of cancer in such settings is relatively
low (4).

8

Considering the fact that mammography screening does have risks along with benefits and
the necessity of strengthening and orientating health systems towards NCDs, it is required
to test the validity of mammography in low and middle-income settings and produce
enough evidence for development of policy menu from which guidelines can be adopted
to achieve goals mentioned in Global Action Plan. Critically analyzing the balance of
benefits and risks for producing an age-based invitation policy is a complex decision
problem, but operations research tools have been successful in developing solutions with
required cost-benefit balance. Next section will discuss the literature addressing the
screening decision problems with different operations research tools in different
perspectives.
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CHAPTER 2
LITERATURE REVIEW
In introduction section we discussed the broader challenges faced healthcare systems in
low and middle-income settings, i.e. changing trends of cancer and lack of resources to
address increasing incidence and mortality of cancer. In addition to the broader challenges,
intervention strategies might also have intrinsic complexities in terms of application or
health risks; e.g. mammography can lead to overdiagnosis and overtreatment. Operations
Research tools have been successful in performing cost-effective and cost-benefit analysis
of different intervention strategies for cancer prevention and control.
2.1 Simulation methods

Simulation models have proven to be an effective tool in testing and/or comparing costeffectiveness of different strategies available for decision maker. While simulations models
can be classified on numerous categories, one important distinction for the models is
whether the model is empirically based shallow model or biologically based deep model
(18). Stage shift model, an example of shallow model, simulate the diagnosis events in
process of comparing the cost-effectiveness of different strategies, e.g. in comparison to
no screening a specific screening strategy can result into diagnosis in less advance stage or
early diagnosis in the same stage. But stage shift models do not delineate the trajectory
followed in result of any specific event, therefore cannot be inclusive of the small details,
e.g. if diagnosis is a case of overdiagnosis then the resulting life years saved should not be
considered in the benefits of the strategy, but stage shift cannot incorporate such details
(18). Opposed to shallow models, deep models are biologically inspired models where the
10

underlying process of leading to results is considered, e.g. the natural progression of tumor.
As deep models are generally much more detailed than a shallow model, time required for
their development and data required to tune the parameters is higher than shallow models.
The comprehensive nature of the deep models also makes them adaptable to the changes
and therefore can address broader policy question (18).
Stout et. al. (19), presents a model which evaluates lifetime cost and number of QALY for
women aged 40 years or older, in the period of 1990 to 2000, for different breast cancer
screening scenarios. Datum scenario was a one with no screening and other 65 scenarios
were compared with datum. Out of 65 other scenarios, 64 were designed with different
variations of starting age, ending age and frequency of screening, and one scenario was
screening which actually took place from 1990 to 2000 in the USA. Authors found 11
strategies on the efficient frontier and the annual screening strategy from 40 to 70 years of
age (closely resembling with the contemporary practices) was one of them with the highest
cost. Therefore, this study with use of deep model presents alternative strategies which can
be adopted with lower costs.
Study report from U.S. Preventive Services Task Force (20), also presents comparative
analysis of 20 different screening schedules based on benefits (life years gained), resource
usage (number of mammograms) and harms (false positive rate, unnecessary biopsies and
overdiagnosis). Results from 6 independently developed models; deep models, developed
with common input data on incidence, mortality, treatment algorithm and few model
specific data variables; were compared on the metrics mentioned above. Population
considered in the models is the cohort of women born in 1960 and tracked from age 25
years for their whole life. Results indicated that the policies which suggested screening in
11

age group 40-49 had relatively higher harms than the policies which did not include this
specific age group. In resulting 8 non-dominant strategies out of the total 20 screening
schedules, 6 schedules started from age 50 and all but one schedule was biennial. Hence,
this study also presented cost-effectiveness analysis which provided a quantitative
comparison of different screening policies with help of deep model.
2.2 Markov Decision Process
Özekici and Pliska (21), by assuming the disease risk and test properties are stationary,
develop an infinite horizon MDP model minimizing the cost of inspection, false positives,
treatment and death. They present a policy to screen, for a person whose terminal medical
care costs and dollar value assigned to each loss of life is higher than 55000 USD. Maillart
et. al. (22), considering age specific risk and imperfect tests (false-positive/negative), they
present POMDP model maximizing the probability of survival to investigate screening
frequency of breast cancer for premenopausal and postmenopausal women. Ayer et. al.
(23), formulate a finite-horizon POMDP model maximizing the QALY lived during a
lifespan. They have considered age-dependent disease progression, test accuracies and
probability of self-detection and show that the individualized personal screening schedules
resulted into higher QALY than the screening guidelines, simultaneously decreasing the
total number of mammograms.
Kong and Mondschein (24), develop a stochastic dynamic programming approach in finite
planning horizon, minimizing the total expected lifetime cost they determine
individualized mammography guidelines which will enable dynamic tracking of patient’s
risk factor. As the optimal policy generated by their model is very aggressive for low-risk
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patient while is very conservative for high-risk patients, they also suggest segmenting the
population according to the breast cancer risk for better tracking of risk factors and better
policy results. Kong et. al. (25) used the same model to present and analyze mammography
screening policy for Chilean population.
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CHAPTER 3
MOTIVATION
Although randomized control trials provide evidence regarding efficacy of the screening
methods, the stringent barriers on timeline of the study, population under consideration and
type of screening technology being evaluated in the trial makes usability of the evidence
limited (18). Trials cannot determine whether the evidence collected with the current cohort
will also hold for another (18). Also, the screening and follow-up schedule which have
been followed throughout the trial also needs to be compared with multiple other schedules
for testing the effectiveness and finding the non-dominant strategies (18). Lastly, the
decision regarding development of the screening guidelines cannot wait until the
completion of any specific trial (18). Modeling techniques can leverage findings from trials
and generate more comprehensive cost-benefit analysis of the screening schedule which
are of interest to decision maker but are not covered in randomized trials. Furthermore,
given the current developments in screening technologies, treatment and understanding of
the disease, finding optimal screening strategy for any population is a moving target
problem (18), which motivates the development of more flexible models acceptable to the
current developments and are designed specifically for different population settings.
Developed models till now are suited to the data availability in high-income countries
(HIC), while data availability and data quality in LMICs are low, even today. General
approach used to address LMIC conditions was to extrapolate evidence from models
developed for HIC. The models which were developed for LMICs, lacked technical depth
(26) (17). Hence, it is utmost important to develop mathematical models encapsulating
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epidemics and demographics specific to LMICs while considering the constraints on data
availability, data quality and healthcare-resources to address the worsening incidence and
mortality of cancer.
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CHAPTER 4
RESEARCH QUESTION
In the background section we discussed how cancer is imparting incremental burden on
health systems in low-middle income countries due increasing incidence and mortality of
cancer. We also discussed the different aspects of the cancer control problem, to
summarize,
1. In spite of the drastic increase in the incidence and mortality, healthcare system’s
spending and orientation of control policies towards cancer has not increased in
low-middle income countries.
2. Out of all the cancer, burden is mostly imparted due to cancers amenable to
treatment, i.e. breast cancer, colorectal cancer and cervical cancer. As treatment of
cancer is morbid, expensive and often ineffective in advanced stages, cancer control
hinge on early diagnosis.
3. Moreover, breast cancer incidence in women is thrice the incidence of next most
common cancers.
4. Due to low Population Attributable Factor (PAF), breast cancer cannot be
effectively prevented and population sub-setting for better utilization of screening
resource is also not possible. Therefore, age-based screening becomes next best
strategy for breast cancer control.
5. Guidelines by WHO and practices observed in low-middle income countries do not
show consensus on schedules of age-based mammography screening.
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6. Evidence of effectiveness of mammography screening specific to population in
low-middle income setting is absent and decision making in such setting greatly
depend upon data from trials conducted in high-income countries or modeling
studies done specific to high-income setting population.
Considering all the challenges mentioned above, in this thesis we have considered the case
of breast cancer in lower-middle income population setting. Following this selection of
problem, we will present a methodology to address the question of cost-effective age-based
breast cancer screening schedule for a lower-middle income country for different values of
willingness to pay of service provider (USD amount assigned to each life year lived), i.e.,
“What is cost-effective mammography screening schedules specific to a population for
different values of willingness to pay?”
Development of mathematical model will provide necessary evidence required by decision
makers in development of the screening guidelines for breast cancer in the country under
consideration. The model we present is developed for breast cancer but has potential to
produce evidence on cervical cancer and colorectal cancer with respective changes.
Addressing issues in screening schedule development and reinforcing the decisions with
evidence on breast cancer, colorectal cancer and cervical cancer (these three cancers being
responsible for major proportion of burden) will significant help low and middle-income
countries in managing the increasing burden due to cancer.
Next section will discuss the developed method in detail followed by discussion and
conclusion.
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CHAPTER 5
METHODOLOGY
5.1 Approach

Figure 1: Model structure

The developed model has three main components, first is parameterization of the natural
history of breast cancer, second is finite horizon Markov decision process model for
computing optimal mammography schedules and finally a compartmental simulation
model for simulating the screening schedules either computed from MDP model or the
suggested screening guidelines from previous literature. These three models are arranged
in series as shown in Figure 1, where second and the third model take input from the
previous model and literature. Parametrization model, the first one, takes data input from
GLOBOCAN 2012 database for age-specific incidence and mortality of breast cancer,
literature and demographic projection software ‘Spectrum’. The literature input for the
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parameterization model includes distribution of diagnosed cases over cancer stages,
observed specifically in a country. For the optimization model, literature input includes
cost and test specific parameters for mammography screening. Lastly, for the simulation
model for outcomes and economic analysis, the literature input contains set of different
policies observed in practice or mentioned in WHO guidelines.
Following sections will discuss each block of the mathematical model, from
parameterization to simulation model, in detail.
5.2 Method

5.2.1 Overview of breast cancer disease progression

We assumed that breast cancer initiated first as carcinoma in-situ (CIS), i.e. women could
transition from healthy to CIS. In the absence of diagnosis, the disease naturally progresses
through the invasive carcinoma preclinical stages local, regional, and distant, that we refer
to as system states. From any of these preclinical disease states persons could transition to
clinical states through diagnosis based on symptoms or through screening. Upon transition
to a clinical state through diagnosis, persons remain in the state at diagnosis and face a
certain rate of death based on treatment efficacy at the cancer stage at diagnosis. For
persons who were diagnosed, we did not explicitly model recurrence of disease, we only
applied an average stage-specific rate of survival. We present the flow diagram in Figure
2.
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Figure 2: Flow diagram of breast cancer onset and state progression

We assumed that onset rates, i.e., the rate of transition from healthy to CIS, and diagnostic
rates, i.e., the rates of transition from preclinical to clinical states, are dependent on the
population under consideration and developed a two-step Markov process methodology for
estimation of these rates. We assumed rates of natural progression through cancer stages,
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i.e., from preclinical CIS to local, to regional, and to distant, do not vary by geographical
region and used pre-estimated rates from the literature. We present the data estimates taken
from published literature in Appendix A.1.
5.2.2 Two-Step Markov Process (TSMP) methodology for parametrization of the
natural onset and progression of cancer

The TSMP divides the estimation of population-specific onset rates of disease and
diagnostic rates into two Markov process models, each defined over different state spaces.
In the first step, we define the disease onset and progression as a discrete-time Markov
process,
𝑿 = {𝑋𝑡 ; 𝑡 ≥ 0, Ω, ℙ}

(1)

with a collapsed state space,
Ω = {[𝐻𝑎 ], [𝑈𝑎 ], [𝐷𝑎 ]}
Where,
𝑎 = 𝑎𝑔𝑒, and
health states 𝐻𝑎 = Healthy, 𝑈𝑎 = Undiagnosed, and 𝐷𝑎 = Diagnosed,
(see Figure 3 for a flow diagram, and Table 1: Overview of notations for the two-step
Markov process parameterization methodology for a list of notations).

Figure 3: Flow diagram for the collapsed states space in the first step of the Markov
process parameterization
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Table 1: Overview of notations for the two-step Markov process parameterization
methodology
𝐼𝑎

Incidence of cancer at age 𝑎, from GLOBOCAN

𝐼̅𝑎

Incidence of cancer at age 𝑎, from simulation model

∆𝑡

time step in the simulation model
steady state population in the state space 𝑍 (equation), from the

𝜌𝑡
simulation model,
𝑑𝑖,𝑎
𝑠𝑗
𝑝𝑖,𝑎

diagnostic rate of cancer in stage 𝑖 and age 𝑎,
percentage of diagnosed cases of cancer in the stage ‘j’
prevalence in pre-clinical state 𝑖 at age 𝑎

𝜆𝑖

dwell rate for cancer stage 𝑖

𝐼𝑖,𝑎

Incidence of cancer stage 𝑖 at age 𝑎 from GLOBOCAN data

̅̅̅̅
𝐼𝑖,𝑎

Incidence of cancer stage 𝑖 at age 𝑎 from, from simulation model

clustering together all micro-states of the disease; and ℙ is the transition probability matrix.
We estimate age-specific onset rates using an iterative analytical model derived using the
Markov chain 𝑿. The technical details and proofs leading to the analytical model are
presented in (27), here we only summarize the outline of the algorithm in
Table 2: Algorithm for computing age-specific onset rate of cancer.

Table 2: Algorithm for computing age-specific onset rate of cancer
Initialize 𝜋𝐻0 = 𝐴0 ; 𝜋𝑈0 = 0; and 𝑃𝐻0 𝑈0 = 0; Set 𝑎 = 1, the youngest age-group of cancer
onset (we assumed age 15 for breast cancer).
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Step 1: Calculate in-situ onset rate
𝑃𝐻𝑎 𝑈𝑎
=

−(𝑎−𝑘)𝜆𝑖
𝐼𝐷𝑎 𝑐𝑎 − ∑𝑎−1
) − ∑𝑖 𝑠𝑖 (1 − 𝑒 −(𝑎−1−𝑘)𝜆𝑖 )](∏𝑗=𝑘:𝑎+1 𝑒 −𝜇𝑗 ))
𝑘=0 (𝜋𝐻𝑘 𝑃𝐻𝑘 𝑈𝑘 [∑𝑖 𝑠𝑖 (1 − 𝑒

𝐴𝑎 [∑𝑖 𝑠𝑖 (1 − 𝑒 −𝜆𝑖 )](𝑒 −𝜇𝑎 ) − 𝐼𝐷𝑎 𝑐𝑎

Where.
1
𝜆𝑖

1

1

= ∑𝑖𝑗=0 𝑝 ; if 𝑝𝑗 are a function of age at disease onset then 𝜆
𝑗

𝑖,𝑎

1

= ∑𝑖𝑗=0 𝑝

𝑗,𝑎

Then, disease onset rate at age 𝑎 is estimated as
𝜃𝑎 = −ln (1 − 𝑃𝐻𝑎 𝑈𝑎 )

Step 2: Calculate prevalence of healthy state:

𝜋𝐻𝑎 =

𝐴𝑎 − ∑𝑎−1
𝑘=0 (𝜋𝐻𝑘 𝑃𝐻𝑘 𝑈𝑘 𝑃(𝑇 ≥ 𝑎 − 𝑘)𝑃(𝑆 ≥ 𝑎 − 𝑘))
1 + 𝑃𝐻𝑎 𝑈𝑎

𝑃(𝑇 ≥ 𝑎 − 𝑘)𝑃(𝑆 ≥ 𝑎 − 𝑘) = ∑ 𝑠𝑖 (1 − 𝑒 −(𝑎−1−𝑘)𝜆𝑖 ) ∏ 𝑒 −𝜇𝑗
𝑖

𝑗=𝑘:𝑎

Where,
1
𝜆𝑖

1

1

= ∑𝑖𝑗=0 𝑝 ; if 𝑝𝑗 are a function of age at disease onset then 𝜆
𝑗

𝑖,𝑎

1

= ∑𝑖𝑗=0 𝑝

𝑗,𝑎

Step 3: Increment 𝑎 by 1; if 𝑎 is less than the maximum age go to step 1, else stop.

In the second step, we estimated diagnostic rates in each stage of cancer, i.e.,
transition rates from preclinical to clinical states (𝑑𝑖,𝑎 ), by using a simulation-based
optimization method. In this method we simulate the Markov process 𝒀 = {𝑌𝑡 ; 𝑡 ≥
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0, 𝑍, ℚ}, where state space is 𝑍 = {[𝐻𝑎 ], [𝑈𝑖,𝑎 ], [𝐷𝑖,𝑎 ]}, and rate matrix ℚ, which
corresponds to the to the flow diagram in Figure 2.
The objective of the simulation-based optimization model is to minimize the sum
of square errors between the simulated cancer incidence (𝐼̅𝑎 ) and the GLOBOCAN
predicted incidence (𝐼𝑎 ) (28). For completeness, we first present this earlier version of the
model formulation before discussing the modifications specific to a data-limited setting
that has partial screening programs. The objective function was formulated as
2

𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒𝑑𝑖,𝑎 ∑𝑎(𝐼̅𝑎 − 𝐼𝑎 ) , 𝑑𝑖,𝑎 ≥ 0, ∀𝑖, 𝑎
(2)
As the analytical form of 𝐼̅𝑎 are unknown, but the value of the objective function can be
evaluated at different points of the decision parameters 𝑑𝑖,𝑎 ≥ 0, ∀𝑖, 𝑎, with simulation.
Here, for any specific 𝑑𝑖,𝑎 values, we simulated the Markov Process 𝒀 over time 𝑡 using
𝝆𝑡+1 = 𝝆𝑡 + 𝝆𝑡 ℚ∆𝑡 until it reached state steady, i.e.,
𝝆 = 𝝆 + 𝝆ℚ∆𝑡
(3)
where 𝝆 is a vector of state distribution at steady state and ℚ is the rate matrix.
We estimated 𝐼̅𝑎 using following equation,
𝐼̅𝑎 = ∑𝑖 𝜌𝑈 𝑖,𝑎 𝑑𝑖,𝑎 ,
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where 𝜌𝑈 𝑖,𝑎 is the steady state value for state 𝑈𝑖,𝑎 (denoting the prevalence in pre-clinical
cancer stage 𝑖 at age 𝑎), which can be estimated by expansion of equation (3) as
𝜌𝑈 𝑖,𝑎 = 𝜌𝑈 𝑖,𝑎 + 𝜌𝑈𝑖−1,𝑎−1 𝜆𝑖−1,𝑎 − 𝜌𝑈 𝑖,𝑎−1 (𝜆𝑖,𝑎 + 𝑑𝑖,𝑎 + 𝜇𝑖,𝑎 )

In the previously presented TSMP model in (27), because of the assumption that
diagnosis is only symptomatic and that the probability of showing symptoms are higher in
advanced disease stages, i.e., 𝑑𝑖,𝑎 > 𝑑𝑖−1,𝑎 , the distribution of the stage at diagnosis was a
𝑑

good approximation for the ratio of stage-specific diagnostic rates. That is, 𝑑 𝑖,𝑎 = ∑𝑖𝑗=0 𝑠𝑗 ,
3,𝑎

where 𝑠𝑗 is the proportion diagnosed in stage 𝑗, and 𝑑𝑖,𝑎 is the diagnostic rate at state 𝑖 and
age 𝑎. Therefore, for the terms in the objective function in equation (2) we could write
2

2

(𝐼̅𝑎 − 𝐼𝑎 )2 = (∑𝑖 𝜌𝑈 𝑖,𝑎 𝑑𝑖,𝑎 − 𝐼𝑎 ) = (∑𝑖 𝜌𝑈 𝑖,𝑎 (𝑑3,𝑎 ∑𝑖𝑗=0 𝑠𝑗 ) − 𝐼𝑎 ) ≈ 𝑓(𝑑3,𝑎 ) (4)
Therefore, the only unknown values in the objective function in equation (2) were the
diagnostic rates in the last stage of cancer (𝑑3,𝑎 ), as the steady state values in the preclinical states, 𝜌𝑈 𝑖,𝑎 , are estimated numerically from the simulation of the Markov model
in equation (3) as discussed above. The resulting objective function was
2

𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒𝑑3,𝑎 ∑𝑎 (∑𝑖 𝜌𝑈 𝑖,𝑎 (𝑑3,𝑎 ∑𝑖𝑗=0 𝑠𝑗 ) − 𝐼𝑎 )

(5)

and the decision variables 𝑑3,𝑎 ∀𝑎 were solved iteratively for each 𝑎. However, in
the case of countries such as Peru, certain populations have undergone screening based on
recommendations and regional programs help in country prior to 2012 (the latest incidence
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data available at the time of this work was for year 2012), and thus, the assumption 𝑑𝑖,𝑎 >
𝑑𝑖−1,𝑎 does not hold. Therefore, we modified the objective function in equation (5) to
2

𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒𝑑𝑖,𝑎,∀𝑖,𝑎 ∑𝑖,𝑎 (𝜌𝑈 𝑖,𝑎 (𝑑𝑖,𝑎 ) − 𝐼𝑎 ) , 𝑑𝑖,𝑎 ≥ 0 ∀𝑖, 𝑎

(6)

Thus, the number of decision variables (the unknown values) now increase to include
diagnostic rates in all stages 𝑖 and ages 𝑎, i.e., 𝑑𝑖,𝑎 ∀𝑖, 𝑎. This creates a large number of
decision variables. As the number of decision variables increases, ascertaining the
convergence of a solution algorithm to the global optima becomes more challenging. We
address this by showing below that the optimization problem in equation (6) is separable
both on 𝑖 and 𝑎 and thus equation (6) can be converted to 𝑖𝑎 number of sub-problems. Each
sub-problem can then be solved separately but iteratively for 𝑑𝑖,𝑎 , iterating over each
𝑖 and 𝑎 (see below). We further test for the convexity of each sub-problem (see Appendix
A.2).
Remark 1: We can rewrite equation (6) as,
2

𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒𝑑𝑖,𝑎 (𝜌𝑈 𝑖,𝑎 (𝑑𝑖,𝑎 ) − 𝐼𝑎 ) , 𝑑𝑖,𝑎 ≥ 0

(7)

for each combination of 𝑖, 𝑎 pair thus generating 𝑖𝑎 number of sub-problems. Each
function can then be solved separately for 𝑑𝑖,𝑎 but iteratively over age 𝑎 starting from the
youngest age and, within each age, iteratively over cancer state 𝑖 starting with the earliest
disease state.
Proof:
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Using the expression for 𝜌𝑈 𝑖,𝑎 , from the expansion of the Markov process in
equation (3) discussed above, and multiplying by 𝑑𝑖,𝑎 we can write

𝜌𝑈 𝑖,𝑎 𝑑𝑖,𝑎 = [𝜌𝑈 𝑖,𝑎 + 𝜌𝑈𝑖−1,𝑎−1 𝜆𝑖−1,𝑎 − 𝜌𝑈 𝑖,𝑎−1 (𝜆𝑖,𝑎 + 𝑑𝑖,𝑎 + 𝜇𝑖,𝑎 )] 𝑑𝑖,𝑎

(8)

In equation (8), for 𝑖 = 0 (the in-situ stage) 𝜆𝑖−1,𝑎−1 = 𝜃𝑎−1 the cancer onset rate, and for
all other values of 𝑖 (i.e., local, regional, and distant stages) 𝜆𝑖−1,𝑎−1 are the progression
rates (see Figure 2); and 𝜇𝑖,𝑎−1 are the mortality rates. Values for 𝜆𝑖−1,𝑎−1 and 𝜇𝑖,𝑎−1 are
known. When 𝑖 = 0 (the in-situ stage) 𝜌𝑈𝑖−1,𝑎−1 = 𝜌𝐻𝑎−1 denoting the steady state value in
healthy (i.e., prevalence of healthy stage), and under all other values of 𝑖, 𝜌𝑈𝑖−1,𝑎−1 are the
steady state values in the pre-clinical states (i.e., prevalence of pre-clinical cancer stages).
For any given 𝑖, 𝑎 pair, from Remark 2 and its proof below, the steady state values for
𝜌𝑈𝑖,𝑎−1 and 𝜌𝑈𝑖−1,𝑎−1 , and solution to 𝑑𝑖,𝑎−1 are known. Therefore, for any value of 𝑑𝑖,𝑎 , the
steady state value for 𝜌𝑈𝑖,𝑎 can be calculated through simulation of the Markov process in
equation (3). As such, the only unknown value in equation (8) will then be 𝑑𝑖,𝑎 which can
be solved by applying a non-linear solver to the optimization problem in equation (7). To
identify convergence of the algorithm to global optima, we test for the convexity of
equation (7), which we discuss in Appendix A.2.
This completes the proof.
Remark 2: If we iteratively solve for 𝑑𝑖,𝑎 using equation (8) by iterating over 𝑎 and, within
each 𝑎, iterate over 𝑖, then, for any given 𝑖, 𝑎 pair, the steady state values for 𝜌𝑈𝑖,𝑎−1 and
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𝜌𝑈𝑖−1,𝑎−1 , and the solution to 𝑑𝑖,𝑎−1 are known. Thus, the only unknown term in equation
(8) is 𝑑𝑖,𝑎
Proof:
We prove this by applying mathematical induction on equation (8)
For 𝑖 = 0, 𝑎 = 1,

𝜌𝑈 0,1 𝑑0,1 = [𝜌𝑈 0,1 + 𝜌𝐻0 𝜃1 − 𝜌𝑈 0,0 (𝜆0,𝑎 + 𝑑0,𝑎 + 𝜇𝐻,𝑎 )] 𝑑0,1
Then, the only unknown value is 𝑑0,1 because 𝜌𝑈 0,0 = 0 and 𝜌𝐻0 is the actual
prevalence of healthy persons in age 0 (obtained from population demographics) as
the first age for disease risk is 1, and all other parameters are known as discussed
in proof of Remark 1.
Assuming the proof holds for 𝑖 = 𝑚, 𝑎 = 1,
for = 𝑚 + 1 , 𝑎 = 1
𝜌𝑈 𝑚+1,1 𝑑𝑚+1,1
= [𝜌𝑈 𝑚+1,1 + 𝜌𝑈𝑚,0 𝜆𝑚,1 − 𝜌𝑈 𝑚+1,0 (𝜆𝑚+1,1 + 𝑑𝑚+1,1 + 𝜇𝑚+1,1 )] 𝑑𝑚+1,1
Then, the only unknown parameter is 𝑑𝑚+1,1 as 𝜌𝑈𝑚,0 = 0 and 𝜌𝑈 𝑚+1,0 = 0 as
the first age of disease risk is 1.
For = 0 , 𝑎 = 2
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𝜌𝑈 0,2 𝑑0,2 = [𝜌𝑈 0,2 + 𝜌𝐻1 𝜃2 − 𝜌𝑈 0,1 (𝜆𝑖,2 + 𝑑𝑖,2 + 𝜇𝑖,2 )] 𝑑0,2
Then, the only unknown parameter is 𝑑0,2 because 𝜌𝐻1 = 𝜌𝐻1 − 𝜌𝐻0 (𝜃1 + 𝜇𝐻,1 )
can be estimated through steady state simulation of equation (3) and 𝜌𝑈 0,1 was
estimated previously under = 0 , 𝑎 = 1.
Assuming the proof holds for 𝑖 = 𝑚, 𝑎 = 2,
for = 𝑚 + 1 , 𝑎 = 2
𝜌𝑈 𝑚+1,2 𝑑𝑚+1,2
= [𝜌𝑈 𝑚+1,2 + 𝜌𝑈𝑚,1 𝜆𝑚,2 − 𝜌𝑈 𝑚+1,1 (𝜆𝑚+1,2 + 𝑑𝑚+1,2 + 𝜇𝑚+1,2 )] 𝑑𝑚+1,2
Then, the only unknown parameter is 𝑑𝑚+1,2 as 𝜌𝑈𝑚,1 and 𝜌𝑈 𝑚+1,1 were
estimated above under = 𝑚 , 𝑎 = 1 and 𝑖 = 𝑚 + 1 , 𝑎 = 1, respectively
Finally, assuming the proof holds for any 𝑖 and 𝑎 = 𝑘,
for any 𝑖 , and 𝑎 = 𝑘 + 1

𝜌𝑈 𝑖,𝑘+1 𝑑𝑖,𝑘+1 = [𝜌𝑈 𝑖,𝑘+1 + 𝜌𝑈𝑖−1,𝑘 𝜆𝑖−1,𝑘+1 − 𝜌𝑈 𝑖,𝑘 (𝜆𝑖,𝑘+1 + 𝑑𝑖,𝑘+1 + 𝜇𝑖,𝑘+1 )] 𝑑𝑖,𝑘+1
Then, the only unknown parameter is 𝑑𝑖,𝑘+1 as 𝜌𝑈𝑖−1,𝑘 and 𝜌𝑈 𝑖,𝑘 were estimated
above under any 𝑖and 𝑎 = 𝑘.
This completes the proof.
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Therefore, in this way we are first making the objective function fit for the setting of
countries such as in Latin America, where diagnosis is not entirely symptomatic, i.e.
changing the objective function from equation (5) to equation (6). By doing so, we are
increasing the size of the problem as equation (6) does have 4 times more decision variables
(𝑑𝑖,𝑎 , , 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑒𝑐𝑖𝑠𝑖𝑜𝑛 𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒𝑠 = 400)

than

the

equation

(5)

(𝑑4,𝑎 , 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑒𝑐𝑖𝑠𝑖𝑜𝑛 𝑣𝑎𝑟𝑖𝑎𝑏𝑙𝑒𝑠 = 100). Proving the separability of the objective
function coverts the larger problem into 400 sub-problems, each having only one decision
variable, if solved iteratively from earliest disease state and age. Figure 4, gives a visual
representation of the optimization process, starting from earliest cancer state and age.
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Figure 4: Iterative process of solving sub-optimization problems for diagnosis rates

5.2.3 A Markov decision process (MDP) to identify optimal screening intervals for
mammography

We formulated the problem of identifying an optimal screening strategy, specifically,
what ages to screen, as a finite horizon MDP defined as {𝑋𝑠 , 𝐷𝑠 ; 𝑍, 𝐴, ℙ𝑎 , 𝑅𝑎 } (see Table
3: Overview of the notations used in the Markov decision process model for notations),
Table 3: Overview of the notations used in the Markov decision process model
ℙ

Transition probability matrix

𝐴

Action space
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𝑍

{[𝐻𝑎 ], [𝑈𝑖,𝑎 ], [𝐷𝑖,𝑎 ]}

𝑘

{[𝐻𝑎 ], [𝑈𝑖,𝑎 ]}
value function of the Bellman equation for state 𝑖 ′ , at stage 𝑠, if action

𝑉(𝑖 ′ , 𝑠, 𝑎)
𝑎 is taken
𝜋𝑖 ′
𝑟(𝑖 ′ , 𝑠, 𝑎)

steady state distribution for state 𝑖 ′ ∈ 𝑘
expected reward in state 𝑖 ′ and stage 𝑠, under action 𝑎
probability of transition from 𝑖 ′ to 𝑗 , at stage 𝑠, under action 𝑎 , where

′

𝑝(𝑖 , 𝑠, 𝑎, 𝑗)
𝑗 ∈𝑍
𝑎∗ (𝑘, 𝑠)

optimal action in state 𝑘 at stage 𝑠

Where,
𝑠 = 1 𝑡𝑜 100 are the decision making stages, here representing individual ages,
𝑋𝑠 𝜖Z is the disease state at stage 𝑠, defined over state space Z = {[𝐻𝑎 ], [𝑈𝑖,𝑎 ], [𝐷𝑖,𝑎 ], 𝑀},
where [𝐻𝑎 ], [𝑈𝑖,𝑎 ], [𝐷𝑖,𝑎 ] are healthy, preclinical, and clinical states as in the Markov
process model, and 𝑀 denotes a mortality state,
𝐴 is the action space which is a set of possible decisions at stage 𝑠, 𝐴𝑖 =
{𝑆𝑐𝑟𝑒𝑒𝑛(1), 𝐷𝑜 𝑛𝑜𝑡 𝑆𝑐𝑟𝑒𝑒𝑛(0)} ∀𝑖 ′ ∈ 𝑘 = {[𝐻𝑎 ], [𝑈𝑖,𝑎 ]}, 𝐴𝑖 =
{𝐷𝑜 𝑛𝑜𝑡ℎ𝑖𝑛𝑔}∀𝑖𝜖{[𝐷𝑖,𝑎 ], 𝑀}
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𝐷𝑠 𝜖𝐴 is the decision taken at stage 𝑠 (choosing from set 𝐴, a set of possible decision
choices),
ℙ𝑎 is the transition probability matrix for action 𝑎, with each element 𝑝(𝑖 ′ , 𝑠, 𝑎, 𝑗)
representing the probability of transitioning from state 𝑖 ′ to state 𝑗 if the system is in stage
𝑠 and action 𝑎 is taken (expressions for transition probabilities are mentioned in Appendix
A.4), and 𝑅𝑎 is the immediate reward for action 𝑎, with 𝑟(𝑖 ′ , 𝑠, 𝑎, 𝑗) representing each
element of the matrix.
The problem is then to solve for the optimal values of 𝐷𝑠 . Use of MDP in this context is a
well-studied problem (26) so we do not discuss further details of the methodology here.
We only show the formulation of the problem in the context of identifying optimal
screening guidelines for any country considering costs of screening and willingness to pay
per quality-adjusted life-year saved.
The above MDP was solved using dynamic programming. In this method, at every stage 𝑠
(representing age) the model chooses to do nothing if 𝑖𝜖{[𝐷𝑖,𝑎 ], 𝑀} and if 𝑖 ′ ∈ 𝑘 =
{[𝐻𝑎 ], [𝑈𝑖,𝑎 ]}, the model either chooses to screen or to not screen by calculating the ‘value’
of each action choice 𝑉(𝑖 ′ , 𝑠, 𝑎), and selecting the action that resulted in the highest values
as the optimal action 𝑎∗ (𝑖 ′ , 𝑠) for that specific disease state (𝑖 ′ ) and age (𝑠) combination,
as follows.
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𝜋𝑖 ′
) [∑ 𝑝(𝑖 ′ , 𝑠, 𝑎, 𝑗)𝑟(𝑖 ′ , 𝑠, 𝑎, 𝑗)
𝑉(𝑖 ′ , 𝑠, 𝑎) = ∑ (
∑
𝜋
𝑚∈ 𝑘 𝑚
′
𝑗∈𝑍

𝑖 ∈𝑘

(9)

+ ∑ 𝑝(𝑖 ′ , 𝑠, 𝑎, 𝑗)𝐽∗ (𝑖 ′ , 𝑠 + 1)]
𝑗∈𝑍

∀𝑎 ∈ 𝐴, ∀ 𝑖 ′ ∈ 𝑘 = {[𝐻𝑎 ], [𝑈𝑖,𝑎 ]},
𝑎∗ (𝑖 ′ , 𝑠) = 𝑎𝑟𝑔 𝑚𝑎𝑥𝑎∈𝐴 𝑉(𝑖 ′ , 𝑠, 𝑎) , ∀ 𝑖 ′ ∈ 𝑘

(10)

𝐽∗ (𝑖 ′ , 𝑠) = 𝑟(𝑖 ′ , 𝑠, 𝑎∗ (𝑖 ′ , 𝑠)) + ∑ 𝑝(𝑖 ′ , 𝑠, 𝑎 ∗ (𝑖 ′ , 𝑠), 𝑗)𝐽∗ (𝑖 ′ , 𝑠 + 1)

(11)

𝑗∈𝑍

Note that with the above equations all 𝑖 ′ ∈ 𝑘 = {[𝐻𝑎 ], [𝑈𝑖,𝑎 ]}, will have the same optimal
action, as {[𝑈𝑖,𝑎 ]} are unobservable states.
We set,
0, 𝑖𝑓 𝑗 𝑖𝑠 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦
𝑟𝐿𝑌 . 𝑞𝑗 + 𝑐𝑑 + 𝑐𝑖 , 𝑖𝑓𝑖 ′ ∈ [𝑈𝑖,𝑎 ] 𝑎𝑛𝑑 𝑗 ∈ [𝐷𝑖,𝑎 ]
𝑟(𝑖 ′ , 𝑎, 𝑠 = 𝑛𝑜 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔, 𝑗) =
, and
𝑟𝐿𝑌 . 𝑞𝑗 + 𝑐𝑡 , 𝑖𝑓𝑖 ′ ∈ [𝐷𝑖,𝑎 ] 𝑎𝑛𝑑 𝑗 ∈ 𝑀
𝑟𝐿𝑌 . 𝑞𝑗 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
{

𝑟(𝑖 ′ , 𝑎, 𝑠 = 𝑠𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔, 𝑗) =

0 𝑖𝑓 𝑗 𝑖𝑠 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦
𝑟𝐿𝑌 . 𝑞𝑗 + 𝑐𝑑 + 𝑐𝑖 , 𝑖𝑓 𝑖 ′ ∈ [𝑈𝑖,𝑎 ] 𝑎𝑛𝑑 𝑗 ∈ {[𝐷𝑖,𝑎 ]}
{

𝑟𝐿𝑌 . 𝑞𝑗 + 𝑐𝑡 , 𝑖𝑓𝑖 ′ ∈ [𝐷𝑖,𝑎 ] 𝑎𝑛𝑑 𝑗 ∈ 𝑀
𝑟𝐿𝑌 . 𝑞𝑗 + 𝑐𝑠 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒

where,
𝑐𝑠 = − (𝜁𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦𝑎 𝑐𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑚 + (1 − 𝜁𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦𝑎 )(𝑐𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑚 +
𝑐−𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 )),
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𝑐𝑑 = − (𝑐𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑚 + 𝑐+𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 ),
𝑟𝐿𝑌 = value-per-QALY lived,
where,
1 if j = Ha
0 if j = M
q j = QALY associated with state j, q j = {
,
0 < q j < 1 otherwise
𝜁𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦𝑎 is the specificity of mammography at age a,
𝑐𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑚 is the unit cost of mammography per person,
𝑐−𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 is the cost of follow-up diagnostic tests for a false positive (per person)
𝑐+𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 is the cost of follow-up diagnostic tests for a true positive (per person)
𝑐𝑖 is the initial treatment cost per person, and
𝑐𝑡 is terminal treatment cost per person, which was applied at the final year of life for
women who die from breast cancer.
Values of the above-mentioned parameters are noted in Appendix A.3.
5.2.4 Simulation Model

5.2.4.1 Pseudocode for simulation

The model described above will consider the cross-sectional data and will compute the
optimal screening schedules for given value per QALY. To evaluate performance of such
screening schedules or to compute the outcomes of the screening schedules, we have
developed a simulation model. This simulation model is a compartmental simulation model
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and it computes outcomes collected over 100 years of span screening schedule. Pseudocode
for the simulation model is as follows,
𝐼𝑛𝑖𝑡𝑖𝑎𝑙𝑖𝑧𝑒 𝝆 𝑎𝑛𝑑 𝒍
𝝆 ← 𝑧𝑒𝑟𝑜𝑠(|𝑍|, 𝑠𝑚𝑎𝑥 )
𝒍 ← 𝑧𝑒𝑟𝑜𝑠(|𝑍|, 1)
𝑓𝑜𝑟 𝑎 = 1: 𝑠𝑚𝑎𝑥
𝝆𝒔 ← 𝝅𝒔 𝑨𝒔
𝑓𝑜𝑟 𝑡 = 1: 𝑡𝑚𝑎𝑥
𝑓𝑜𝑟 𝑠 = 𝑠𝑚𝑎𝑥 : 2
𝝆𝒔 ← 𝝆𝒔−𝟏 𝑷(. , 𝒔 − 𝟏, . , 𝒂, . , 𝒔)
𝜌1,1 ← 𝑏𝑖𝑟𝑡ℎ𝑠
𝒍 ← 𝒍 + ∑𝑠 𝝆𝒔

Where,
𝝆 is matrix of population in each state, i.e. total |𝑍|, and each age/stage, i.e. 𝑠𝑚𝑎𝑥 ,
𝑠𝑚𝑎𝑥 is maximum value of age/stage, i.e. 100,
𝑡𝑚𝑎𝑥 is horizon over which policy outcomes are calculated, i.e. 100
𝒍 is life years lived in each state, i.e. 𝑍 = {[𝐻𝑎 ], [𝑈𝑖,𝑎 ], [𝐷𝑖,𝑎 ]},
𝝅𝒔 is stationary distribution over the state space 𝑍, when age/stage is ′𝑠′,
𝑨𝒔 is population distribution over ages
𝑷(. , 𝒔 − 𝟏, . , 𝒂, . , 𝒔) is transition probability matrix at stage/age ‘𝑠 − 1’ under action ‘a’
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5.2.4.2 Impact Metrics

To measure the outcomes of screening schedules identified by our model, we consider two
impact metrics, life-years-saved per 1000 women and false positives per 1000 women,
defined as follows.

Life years saved per 1000 women =

103 (𝐿𝑝𝑜𝑙𝑖𝑐𝑦 − 𝐿𝑏𝑎𝑠𝑒𝑐𝑎𝑠𝑒 )
𝐿𝑏𝑎𝑠𝑒𝑐𝑎𝑠𝑒
⁄𝑡
𝑎𝑣𝑔

False positives per 1000 women =

103 𝑁𝐹𝑃
𝐿𝑏𝑎𝑠𝑒𝑐𝑎𝑠𝑒
⁄𝑡
𝑎𝑣𝑔

Where,
𝐿𝑝𝑜𝑙𝑖𝑐𝑦 = Life years lived in the intervention scenario (optimal screening strategy) over a
100 year period,
𝐿𝑏𝑎𝑠𝑒𝑐𝑎𝑠𝑒 = Life years lived in the base-case (no screening) over a 100 year period,
𝑡𝑎𝑣𝑔 = average life expectancy in the country, thus,

𝐿𝑝𝑜𝑙𝑖𝑐𝑦
𝑡𝑎𝑣𝑔

is an approximation used for

estimating the average number of women in the simulation.
𝑁𝐹𝑃 is the total number of false positives over a 100-year period,
The values used in this application are summarized in Appendix A.3.
5.2.5 Model validation

To validate the model results, we generated additional scenarios of biennial screening
under multiple age groups to compare with results presented in the literature (Figure 3).
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Our model estimations for life years saved per 1000 women under these different screening
schedules

compared

well

with

results

presented

in

(29)

(see
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Figure 5: Model validation: Life years saved per 1000 women compared to current
screening levels3).
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Figure 5: Model validation: Life years saved per 1000 women compared to current
screening levels
(Model group abbreviations: D = Dana-Farber Cancer Institute; E = Erasmus Medical
Center; G = Georgetown University; M = M.D. Anderson Cancer Center; S = Stanford
University; W = University of Wisconsin)

The results in (29), from six independent models, were based on simulations of screening
in women born in 1960 in the United States representative of a screening naïve US
population. Model inputs for parameterization, including pre-screening incidence and
stage at diagnosis distribution, and mammography screen specificity, sensitivity, and costs
were based on (29) and are presented in Appendix A.5.
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CHAPTER 6
DISCUSSION AND CONCLUSIONS
In summary, this thesis presents a new methodology for parameterization of cancer natural
onset and progression for data limited settings such as in low and middle income countries,
and an application of MDP model for estimating optimal number of screens and ages to
screen under different constraints of WTP (numeric value assigned for each life year lived)
or number of possible lifetime screens. Though the literature presents multiple Markov
processes-based parameterization methodologies and MDP models for identifying
screening options, most of these have been applied to or derived from application to
populations in high income countries (HICs). As noted by other researchers in systematic
reviews of economic evidence for informing breast cancer strategies for low and middle income countries (LMICs), the quality of studies specific to LMICs are poor due to lack of
data availabilities. (30) Countries thus adopt to extrapolating strategies or impacts of
strategies from high-income countries, which can be challenging as clinical practices,
health systems, infrastructure availabilities, and culture differ across countries.
We believe the natural progression parameterization methodology presented here, that was
specific to data availabilities in LMIC settings, addresses this key gap. This enables
development of economic analysis that are more tailored to the country, by considering the
population’s disease risk, resource availabilities, and preferences.
Further, current WHO guidelines recommend prioritizing screening ages 50-69 and
strongly recommends against screening for ages 40-49 in low resource settings even if
health systems are relatively strong. The latter is mainly because of the increased number
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of false positives, and increment in the risk of over treatment and over diagnosis due to
false positives in ages 40-49, which require careful monitoring and evaluation that are
usually not available in low resource settings.
The above guidelines were based on RCTs and observational studies conducted in high
income countries and supported by modeling studies. Conducting RCTs in every country
is economically and practically infeasible. We believe, the method presented in this thesis,
that integrates disease burden specific to a country into the modeling, can help evaluate
evidence necessary to understand the risks and benefits of screening women under
alternative strategies.
To test and validate our model, we generated results for United States pre-screening
incidence data and compared with previously presented results (29) (Appendix A.5).
Results consisted of two outcome metrics, first life-years saved and false-positives, both of
which are well matched with the results presented in Mandelblatt et.al. (29).
Further, the optimal screening schedules and its impacts under multiple WTP assumptions
or lifetime screen choices could help countries in planning current screening programs and
their expansion in the future. For example, as the number of lifetime screenings can be
related to infrastructural and resource needs, the scenario to adopt could be based on current
or future resource/infrastructure capacities.
The model is subject to limitations. We only considered heterogeneity by age for incidence
and did not consider any other population characteristics or differences across countries.
Causal factors for differences across countries in the risk of disease could be multiple,
including diet, alcohol and tobacco consumption, competing diseases, or genetic. For
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persons who were diagnosed, we did not explicitly model recurrence of disease, we only
applied an average stage-and age specific rate of survival. We assumed that for persons
with the disease, progression rates in preclinical stages do not vary by populations. The
transition parameters were based on cancer stage, but we did not model heterogeneity in
the cancer subtypes between different populations, or the family history of cancer. We did
not model over-diagnosis of cancers, we only modeled age-specific false positives of
mammography which were incorporated as costs in the MDP model.
Despite these limitations, we believe the methodologies presented for breast cancer from
this study, when applied to a low or middle income country, can have an impactful
contribution to cancer control . We believe, our approach to analysis, of identifying optimal
screening ages and intervals under alternate choices of number of lifetime screens, can help
countries evaluate what options are feasible based on current screening capacities, and
adopt the most cost-effective scenario from among the feasible choices. Further, as
countries are developing an ‘investment case’ to scale-up infrastructure and strengthen
health systems to achieve the goals of mortality reductions from NCDs, pledged under the
Sustainable Development Goals and the WHO Global Action Plan, the method presented
here could help decision-makers determine future infrastructure needs. We believe, the
methodology presented here can be expanded to evaluate interventions in combination or
interventions for other types of cancers, which can further help in the development of the
broader investment case for the prevention of non-communicable diseases.
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APPENDIX A
DATA ASSUMPTIONS FOR PARAMETERIZATION OF CANCER ONSET AND
PROGRESSION

Table 4: Region specific input data for parameterization
Parameters

Value

GENERAL PROGRESSION PARAMETERS

(32) (33) (34)

Progression rates

In-situ to Local (𝜆0,𝑎 )

0.19

Local to Regional (𝜆1,𝑎 )

0.33

Regional to Distant (𝜆2,𝑎 )

0.43

Annual mortality rate (per person year) without
treatment by stage at diagnosis
In-situ

0.08

Local

0.14

Regional

0.23

Distant

0.50

Annual mortality rate (per person year) with
treatment by stage at diagnosis
In-situ (μ1)

0.01

43

Reference

Local (μ2 )

0.02

Regional (μ3 )

0.08

Distant (μ4 )

0.27

REGION-SPECIFIC DATA

(35) (36)
Pre-screening incidence per 1000 persons per
year
Age group

US

0-14

0.00

15-39

0.06

40-44

1.09

45-49

1.72

50-54

1.97

55-59

2.21

60-64

2.60

65-69

2.84

70-74

3.06

75-100

0.29

Distribution of stage at diagnosis in base-case

(37) (38) (39) (36)

Stage

US

In-Situ

4.70%

44

Local

48.30%

Regional

39.50%

Distant

7.50%
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APPENDIX B
TEST FOR CONVEXITY OF THE OPTIMIZATION MODEL FOR
ESTIMATION OF DIAGNOSTIC RATES

In the main paper, diagnostic rates were estimated by solving for the optimization models
2

̅ − 𝐼𝑖,𝑎 ) , 𝑑𝑖,𝑎 ≥ 0 for each combination of cancer stage (𝑖) and age (𝑎)
𝑀𝑖𝑛𝑖𝑚𝑖𝑧𝑒𝑑𝑖,𝑎 (𝐼𝑖,𝑎
̅ and 𝐼𝑖,𝑎 are the simulated and actual cancer incidence in stage 𝑖 and age 𝑎,
pair, where 𝐼𝑖,𝑎
thus solving 𝑖𝑎 number of optimization models. To check for the convergence of the
solution to global optima we test for the convexity of the objective functions.
Specifically, we test for the commonly used convexity test, a function 𝑓(𝑥) that is twice
differentiable on 𝑥 is convex if it is positive semi-definite, i.e., the second derivative
̅ to
𝑓′′(𝑥) ≥ 0 at all points of 𝑥. However, we do not know the analytical form of 𝐼𝑖,𝑎
2

̅ − 𝐼𝑖,𝑎 ) . Therefore, for each
calculate the second derivative of the objective function (𝐼𝑖,𝑎
combination of cancer stage (𝑖) and age (𝑎) pair, we empirically generated the function
̅ by estimation at multiple points of 𝑑𝑖,𝑎 . See Figure 1 and Figure 2 for results on Infor 𝐼𝑖,𝑎
situ and Local stages of cancer and at multiple age groups.
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Figure 6: Incidence vs diagnostic rate for specific age-group and In-situ stage of cancer
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Figure 7: Incidence vs diagnostic rate for specific age-group and local stage of cancer

From the above empirical results, for any given cancer stage and age, the simulated
̅ is approximately a linear or a logarithmic function of diagnostic rates 𝑑𝑖,𝑎 ,
incidence 𝐼𝑖,𝑎
i.e.,
̅ ~𝑐 𝑙𝑛(𝑑𝑖,𝑎 ) + 𝑏 or 𝐼𝑖,𝑎
̅ ~𝑐𝑑𝑖,𝑎 + 𝑏 for some constants 𝑐 and 𝑏.
𝐼𝑖,𝑎
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Writing 𝑥 = 𝑑𝑖,𝑎 ,
̅ ~𝑐 𝑙𝑛(𝑥) + 𝑏 , the second derivative of the objective function (𝐼𝑖,𝑎
̅ − 𝐼𝑖,𝑎 )2 on 𝑥 is
If 𝐼𝑖,𝑎
𝑑2

2

𝑓 ′′ (𝑥) = 𝑑𝑥 2 (𝑐 𝑙𝑛(𝑥) + 𝑏 − 𝐼𝑖,𝑎 ) =

2(𝐼𝑖,𝑎 −𝑏−𝑐 𝑙𝑛(𝑥)+𝑐)
𝑥2

> 0 as 𝐼𝑖,𝑎 > 𝑏

̅ ~𝑐𝑥 + 𝑏, the second derivative of the objective function (𝐼𝑖,𝑎
̅ − 𝐼𝑖,𝑎 )2 on 𝑥 is
And if 𝐼𝑖,𝑎

𝑓

′′ (𝑥)

𝑑2
2
= 2 (𝑐𝑥 + 𝑏 − 𝐼𝑖,𝑎 ) = 2𝑐(𝑐) > 0
𝑑𝑥

̅ − 𝐼𝑖,𝑎 )2 is convex
thus, proving that the objective function (𝐼𝑖,𝑎
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APPENDIX C
ASSUMPTIONS FOR SCREENING PARAMETERS

Table 5: Parameters specific to mammography
Assumption1 (40) (11) (41) (42)

Parameter name
𝜁𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦 (Specificity of
mammogram) for US

𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦 (Sensitivity of
mammogram) for US

Age
<49
50-59
60-69
70-79
Age
<49
50-59
60-69
70-79

Initial
Annual Biennial Triennial
0.85356 0.91812 0.90472 .89606
0.85576 0.91974 0.90498 .90013
0.86576 0.92974 0.91459 .91013
0.88384 0.93602 0.92127 .91974
Initial
Annual Biennial Triennial
0.87158 0.75644 0.81730 0.83026
0.88126 0.77184 0.82155 0.83783
0.90754 0.80298 0.85269 0.86897
0.92611 0.84373 0.88126 0.89640

𝐶𝑠𝑐𝑟𝑒𝑒𝑛 (Screening cost) for US
𝐶𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 (Cost of follow-up
tests if diagnosed) for US

𝐶𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 (Cost of treatment
by stage at diagnosis) for US

1

81.35 USD

Age group
40–49
50–64
65–74
≥75
Stage
In situ
localized
Regional
Distant

True positive, $
2187.89
2053.74
2065.13
1741.3
Initial, $
13055
13055
24682
38119

: Assumptions for cost parameters are taken from working paper
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False positive,
$
1025
1425.48
1432.47
1509.49
Terminal, $
35335
35335
41825
58665

APPENDIX D
TRANSITION PROBABILITY MATRICES
Table 6: Notation used in transition probability matrix
𝜃𝑖,𝑎

Onset rate of breast cancer

𝜆𝑖,𝑎

Dwell rate for cancer stage 𝑖 and age 𝑎

𝑑𝑖,𝑎

Diagnostic rate of cancer in stage 𝑖 and age 𝑎

𝜇𝑎

Natural mortality rate at age 𝑎

𝜇𝑖,𝑎
̿̿̿̿̿

Diseased mortality in cancer stage 𝑖 and age 𝑎

Table 7: Transition probability matrix for action = no screening

50

51

Table 8: Transition probability matrix for action = screening
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Where,
𝑑̅𝑖,𝑎 = (1 − 𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦 )𝑑𝑖,𝑎 + 𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦
− 𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦 (1 − 𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦 )𝑑𝑖,𝑎
𝜆̅𝑖,𝑎 = (1 − 𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦 )𝜆𝑖,𝑎
𝑠 = (1 − 𝜂𝑚𝑎𝑚𝑚𝑜𝑔𝑟𝑎𝑝ℎ𝑦 )

54

APPENDIX E
MODEL VERIFICATION AND VALIDATION ON THE US POPULATIONS

Verifying parameterization of natural history model for the US:
Table 9: Age distribution of the incidence of the onset of preclinical breast cancer
1. Age distribution of the incidence of the onset of preclinical breast cancer
(including ductal carcinoma in situ).
Age

US Study (43)

Our Model

20

0.000

0.001

25

0.002

0.003

30

0.005

0.007

35

0.021

0.019

40

0.046

0.046

45

0.105

0.099

50

0.169

0.172

55

0.233

0.258

60

0.328

0.354

65

0.436

0.457

70

0.563

0.563

75

0.707

0.670

80

0.852

0.799

85

1.000

1.000

2. Compare estimated versus actual incidence at stage diagnosis distribution

55

Incidence per 1,000 women

Incidence per 1,000 women

1.80E-04
1.60E-04
1.40E-04
1.20E-04
1.00E-04
8.00E-05
6.00E-05
4.00E-05
2.00E-05
0.00E+00

Age groups

Age groups
In- Situ (Actual)

Local (Actual)

In- Situ (Estimated)

Incidence per 1,000 women

1.60E-03
1.40E-03
1.20E-03
1.00E-03
8.00E-04
6.00E-04
4.00E-04
2.00E-04
0.00E+00

Age groups

Incidence per 1,000 women

Regional (Actual)

Regional (Estimated)

3.00E-04
2.50E-04
2.00E-04
1.50E-04
1.00E-04
5.00E-05
0.00E+00

Age groups

Distant (Actual)

1.80E-03
1.60E-03
1.40E-03
1.20E-03
1.00E-03
8.00E-04
6.00E-04
4.00E-04
2.00E-04
0.00E+00

Distant (Estimated)
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Local (Estimated)

Figure 8: Comparison of estimated versus actual incidence at stage diagnosis distribution for US

3. Comparison of outcomes
a. Life-Years saved

Life Years Saved per 1,000 women

250

200

150

100

50

0

D

E

G

M

S

W

Our model

Figure 9: Comparison of Life years saved for US from our model with that of six models
developed within NCI and CISNET
(Model group abbreviations: D = Dana-Farber Cancer Institute; E = Erasmus Medical Center; G
= Georgetown University; M = M.D. Anderson Cancer Center; S = Stanford University; W =
University of Wisconsin)

b. False positive rate

57

Figure 10: Comparison of false positives for US from our model with that of six models
developed within NCI and CISNET
(x-axis abbreviations: A = Annual screening schedule in mentioned age-group, B = Biennial
screening schedule in mentioned age-group)
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